Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1261567 | 1.00 | PDE2A (0.31) | PDE2ACTSSPPARDPPARA | |
| SCHEMBL1261842 | 1.00 | PDE2A (0.31) | PDE2ACTSSPPARDPPARA | |
| SCHEMBL1261843 | 0.89 | MEP1B (0.32) | PDE2ACTSS | |
| SCHEMBL1261971 | 0.89 | MEP1B (0.32) | PDE2ACTSS | |
| SCHEMBL1261206 | 0.89 | MEP1B (0.32) | PDE2ACTSS | |
| SCHEMBL1261613 | 0.87 | PDE2A (0.30) | PDE2ACTSS | |
| SCHEMBL4655511 | 0.87 | PDE2A (0.30) | PDE2ACTSS | |
| SCHEMBL1261954 | 0.87 | NR1H2 (0.30) | CTSS | |
| SCHEMBL1261880 | 0.87 | NR1H2 (0.30) | PDE2ACTSS | |
| SCHEMBL1261984 | 0.87 | NR1H2 (0.30) | PDE2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994005-B9 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Bayer Pharma AG (DE) | 2012-01-11 | — | — | EP | disclosed |
| EP-1994005-B1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-7880042-B2 | antiinflammatory agents; (5 alpha ,6 alpha ,8 beta )-2-fluoro-8-methyl-5-[(2-methylquinoline-5-yl)amino]-6-(trifluoromethyl)-5,6,7,8-tetrahydronaphthalene-1,6-diol; side effect reduction | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100298311-A1 | TETRAHYDRONAPHTHALENE DERIVATES, PROCESS FOR PREPARING THEM AND THEIR USE AS ANTIINFLAMMATORY AGENTS | BERGER MARKUS | 2010-11-25 | — | — | US | disclosed |
| EP-1994005-A1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-20070225290-A1 | Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents | BAYER SCHERING PHARMA AG (DE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007104582-A1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225290-A1 | Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents | TNF, IL1B, DHPS | PDE2A 1242/4885CTSS 1392/4885PPARD 557/4885 |
| US-20100298311-A1 | TETRAHYDRONAPHTHALENE DERIVATES, PROCESS FOR PREPARING THEM AND THEIR USE AS ANTIINFLAMMATORY AGENTS | TNF, IL1B, DHPS | PDE2A 1242/4885CTSS 1441/4885PPARD 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.